Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 5, 2012, Pages

  Vannucchi, Guia ^a   Covelli, Danila ^a   Currò, Nicola ^b   Dazzi, Davide ^c   Maffini, Antonia ^a   Campi, Irene ^a   Bonara, Paola ^b   Guastella, Claudio ^b   Pignataro, Lorenzo ^b   Ratiglia, Roberto ^b   Beck Peccoz, Paolo ^a   Salvi, Mario ^a  

^a Istitudo di Ricovero e Cura a Carattere Scientifico Multimedia Scientific and Technology Pole   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Ospedale di Fidenza   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; METHYLPREDNISOLONE; RITUXIMAB; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; AGE; ANTIBODY BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCRINE OPHTHALMOPATHY; FEMALE; GENDER; GRAVES DISEASE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE SUBPOPULATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; THYROID DISEASE; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; FEMALE; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84860751773     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2614     Document Type: Article

References (20)

1. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF 2008 B-lymphocyte contributions to human autoimmune disease. Immunol Rev 223:284-299
2. Rowland SL, Leahy KF, Halverson R, Torres RM, Pelanda R 2010 BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling. J Immunol 185:4570-4581
3. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, Brink R 2004 Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20:785-798
4. Moore PA, Belvedere O, Orr A, Pieri K, La Fleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM 1999 BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260-263
5. Pillai S, Mattoo H, Cariappa A 2011 Bcells and autoimmunity. Curr Opin Immunol 23:721-731
6. Migita K, Ilyassova B, Kovzel EF, Nersesov A, Abiru S, Maeda Y, Komori A, Ito M, Yano K, Yatsuhashi H, Shimoda S, Ishibashi H, Nakamura M 2010 Serum BAFF and APRIL levels in patients with PBC. Clin Immunol 134:217-225
7. Zakarija M, McKenzie JM 1987 The spectrum and significance of autoantibodies reacting with the thyrotropin receptor. Endocrinol Metab Clin North Am 16:343-363
8. Bahn RS 2010 Graves' ophthalmopathy. N Engl J Med 362:726-738
9. Salvi M, Vannucchi G, Campi I, Currò N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P 2007 Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: anopen study. Eur J Endocrinol 156:33-40
10. Khanna D, Chong KK, Afifiyan NF, Hwang CJ, Lee DK, Garneau HC, Goldberg RA, Darwin CH, Smith TJ, Douglas RS 2010 Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 117:133-139.e2
11. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L 2006 The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 154:623-632
12. Gilbert JA, Kalled SL, Moorhead J, Hess DM, Rennert P, Li Z, Khan MZ, Banga JP 2006 Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology. Endocrinology 147:4561-4568
13. Fabris M, Grimaldi F, Villalta D, Picierno A, Fabro C, Bolzan M, De Vita S, Tonutti E 2010 BLyS and April serum levels in patients with autoimmune thyroid diseases. Autoimmun Rev 9:165-169
14. Lleo A, Bowlus CL, Yang GX, Invernizzi P, Podda M, Van De Water J, Ansari AA, Coppel RL, Worman HJ, Gores GJ, Gershwin ME 2010 Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology 52:987-998
15. Vannucchi G, Campi I, Bonomi M, Covelli D, Dazzi D, Currò N, Simonetta S, Bonara P, Persani L, Guastella C, Wall J, Beck-Peccoz P, Salvi M 2010 Rituximab treatmentin patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol 161:436-443
16. Vallerskog T, Heimbürger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, Malmström V 2006 Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 8:R167
17. Toubi E, Kessel A, Slobodin G, Boulman N, Pavlotzky E, Zisman D, Rozenbaum M, Rosner I 2007 Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 66:818-820
18. Pranzatelli MR, Tate ED, Travelstead AL, Verhulst SJ 2011 Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS. Cytokine 53:384-389
19. Reyes LI, León F, González P, Rozas MF, Labarca C, Segovia A, Neira O, Naves R 2008 Dexamethasone inhibits BAFF expression in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Cytokine 42:170-178
20. Zhu XJ, Shi Y, Sun JZ, Shan NN, Peng J, Guo CS, Qin P, Hou M 2009 High-dose dexamethasone inhibits BAFF expression in patients with immune thrombocytopenia. J Clin Immunol 29:603-610